Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer

Kazuto Nosaka; Shiro Suzuki; Toshiaki Yoshikawa; Manami Shimomura; Kazuhisa Kitami; Kosuke Yoshida; Masato Yoshihara; Fumitaka Kikkawa; Tetsuya Nakatsura; Hiroaki Kajiyama

doi:10.21873/anticanres.15289

Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer

Kazuto Nosaka, Shiro Suzuki, Toshiaki Yoshikawa, Manami Shimomura, Kazuhisa Kitami, Kosuke Yoshida, Masato Yoshihara, Fumitaka Kikkawa, Tetsuya Nakatsura, Hiroaki Kajiyama

Research output: Contribution to journal › Article › peer-review

Abstract

Background/Aim: Heat shock protein 105 (HSP105) is overexpressed in various cancers, but not in normal tissues. We investigated the expression levels of HSP105 in cervical cancer and the efficacy of immunotherapy targeting HSP105. Materials and Methods: Previously, we established human leukocyte antigen-A∗02:01 (HLA-A2) restricted HSP105 peptide-specific cytotoxic T lymphocyte (CTL) clones from a colorectal cancer patient vaccinated with an HSP105 peptide. Herein, we evaluated the expression of HSP105 in cervical cancer and cervical intraepithelial neoplasia. Moreover, we tested the effectiveness of an HLAA2-restricted HSP105 peptide-specific CTL clone against cervical cancer cell lines. Results: HSP105 was expressed in 95% (19/20) of examined cervical cancer tissues. Moreover, the HSP105 peptide-specific CTL clone recognized HSP105- and HLA-A∗02:01-positive cervical cancer cell lines and also showed that cytotoxicity against the cervical cancer cell lines depends on HSP105 peptide and HLA class I restricted manners. Conclusion: HSP105 could be an effective target for immunotherapy in patients with cervical cancer.

Original language	English
Pages (from-to)	4741-4751
Number of pages	11
Journal	Anticancer research
Volume	41
Issue number	10
DOIs	https://doi.org/10.21873/anticanres.15289
Publication status	Published - 2021 Oct
Externally published	Yes

Keywords

Cancer germline antigen
Cancer immunotherapy
Cervical cancer
Cytotoxic T lymphocyte clone
Heat shock protein 105

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15289

Cite this

@article{61251baa52624b5fac16f86077ec2870,

title = "Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer",

abstract = "Background/Aim: Heat shock protein 105 (HSP105) is overexpressed in various cancers, but not in normal tissues. We investigated the expression levels of HSP105 in cervical cancer and the efficacy of immunotherapy targeting HSP105. Materials and Methods: Previously, we established human leukocyte antigen-A∗02:01 (HLA-A2) restricted HSP105 peptide-specific cytotoxic T lymphocyte (CTL) clones from a colorectal cancer patient vaccinated with an HSP105 peptide. Herein, we evaluated the expression of HSP105 in cervical cancer and cervical intraepithelial neoplasia. Moreover, we tested the effectiveness of an HLAA2-restricted HSP105 peptide-specific CTL clone against cervical cancer cell lines. Results: HSP105 was expressed in 95% (19/20) of examined cervical cancer tissues. Moreover, the HSP105 peptide-specific CTL clone recognized HSP105- and HLA-A∗02:01-positive cervical cancer cell lines and also showed that cytotoxicity against the cervical cancer cell lines depends on HSP105 peptide and HLA class I restricted manners. Conclusion: HSP105 could be an effective target for immunotherapy in patients with cervical cancer.",

keywords = "Cancer germline antigen, Cancer immunotherapy, Cervical cancer, Cytotoxic T lymphocyte clone, Heat shock protein 105",

author = "Kazuto Nosaka and Shiro Suzuki and Toshiaki Yoshikawa and Manami Shimomura and Kazuhisa Kitami and Kosuke Yoshida and Masato Yoshihara and Fumitaka Kikkawa and Tetsuya Nakatsura and Hiroaki Kajiyama",

note = "Funding Information: The co-author, TN is the inventor of the peptide vaccine patents. TN received fundamental research funding from Takeda Pharmaceutical Co., Ltd. and MEDINET Co., Ltd. The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The remaining Authors report no conflicts of interest. Funding Information: This study was supported in part by the National Cancer Center Research and Development Fund (25-7 and 28-A-8), Japan Agency for Medical Research and Development (AMED, grant no. JP 16ck0106109 h0003), and by Health and Labor Science Research Grants for Research for Promotion of Cancer Control Programs from the Ministry of Health, Labor, and Welfare, Japan. Publisher Copyright: {\textcopyright} 2021 International Institute of Anticancer Research. All rights reserved.",

year = "2021",

month = oct,

doi = "10.21873/anticanres.15289",

language = "English",

volume = "41",

pages = "4741--4751",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

TY - JOUR

T1 - Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer

AU - Nosaka, Kazuto

AU - Suzuki, Shiro

AU - Yoshikawa, Toshiaki

AU - Shimomura, Manami

AU - Kitami, Kazuhisa

AU - Yoshida, Kosuke

AU - Yoshihara, Masato

AU - Kikkawa, Fumitaka

AU - Nakatsura, Tetsuya

AU - Kajiyama, Hiroaki

N1 - Funding Information: The co-author, TN is the inventor of the peptide vaccine patents. TN received fundamental research funding from Takeda Pharmaceutical Co., Ltd. and MEDINET Co., Ltd. The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The remaining Authors report no conflicts of interest. Funding Information: This study was supported in part by the National Cancer Center Research and Development Fund (25-7 and 28-A-8), Japan Agency for Medical Research and Development (AMED, grant no. JP 16ck0106109 h0003), and by Health and Labor Science Research Grants for Research for Promotion of Cancer Control Programs from the Ministry of Health, Labor, and Welfare, Japan. Publisher Copyright: © 2021 International Institute of Anticancer Research. All rights reserved.

PY - 2021/10

Y1 - 2021/10

N2 - Background/Aim: Heat shock protein 105 (HSP105) is overexpressed in various cancers, but not in normal tissues. We investigated the expression levels of HSP105 in cervical cancer and the efficacy of immunotherapy targeting HSP105. Materials and Methods: Previously, we established human leukocyte antigen-A∗02:01 (HLA-A2) restricted HSP105 peptide-specific cytotoxic T lymphocyte (CTL) clones from a colorectal cancer patient vaccinated with an HSP105 peptide. Herein, we evaluated the expression of HSP105 in cervical cancer and cervical intraepithelial neoplasia. Moreover, we tested the effectiveness of an HLAA2-restricted HSP105 peptide-specific CTL clone against cervical cancer cell lines. Results: HSP105 was expressed in 95% (19/20) of examined cervical cancer tissues. Moreover, the HSP105 peptide-specific CTL clone recognized HSP105- and HLA-A∗02:01-positive cervical cancer cell lines and also showed that cytotoxicity against the cervical cancer cell lines depends on HSP105 peptide and HLA class I restricted manners. Conclusion: HSP105 could be an effective target for immunotherapy in patients with cervical cancer.

AB - Background/Aim: Heat shock protein 105 (HSP105) is overexpressed in various cancers, but not in normal tissues. We investigated the expression levels of HSP105 in cervical cancer and the efficacy of immunotherapy targeting HSP105. Materials and Methods: Previously, we established human leukocyte antigen-A∗02:01 (HLA-A2) restricted HSP105 peptide-specific cytotoxic T lymphocyte (CTL) clones from a colorectal cancer patient vaccinated with an HSP105 peptide. Herein, we evaluated the expression of HSP105 in cervical cancer and cervical intraepithelial neoplasia. Moreover, we tested the effectiveness of an HLAA2-restricted HSP105 peptide-specific CTL clone against cervical cancer cell lines. Results: HSP105 was expressed in 95% (19/20) of examined cervical cancer tissues. Moreover, the HSP105 peptide-specific CTL clone recognized HSP105- and HLA-A∗02:01-positive cervical cancer cell lines and also showed that cytotoxicity against the cervical cancer cell lines depends on HSP105 peptide and HLA class I restricted manners. Conclusion: HSP105 could be an effective target for immunotherapy in patients with cervical cancer.

KW - Cancer germline antigen

KW - Cancer immunotherapy

KW - Cervical cancer

KW - Cytotoxic T lymphocyte clone

KW - Heat shock protein 105

UR - http://www.scopus.com/inward/record.url?scp=85116426738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116426738&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15289

DO - 10.21873/anticanres.15289

M3 - Article

C2 - 34593423

AN - SCOPUS:85116426738

SN - 0250-7005

VL - 41

SP - 4741

EP - 4751

JO - Anticancer Research

JF - Anticancer Research

IS - 10

ER -

Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this